1. sayfa ve
Tekrarlanan kayıtlar tek bir kaynakta birleştirilmektedir.
1
Tez

Tez

Kaynak
:
Yazar(lar) :
Konu :
Biyoloji
Yıl :
2015
Therapeutic potentials of fisetin, hesperetin and vitexin on chronic myeloid leukemia and acute myeloid leukemia cells and CML for the first time. There were decreases in the viability/proliferation of K562
and HL60 cells
treated with fisetin, hesperetin
and vitexin. Moreover, the genetic networks derived from this study illuminate some of the biological pathways affected by fisetin
and hesperetin
treatment while providing
2
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Oncology
Yıl :
2008
Childhood Acute Myeloid Leukemia Despite the use of intensive chemotherapy
and hematopoietic stem cell transplantation, approximately one-third of
children with
acute
myeloid
leukemia Instead, advances in the
treatment of
children with AML will require a greater understanding of the biology of the disease, with particular attention to More important, we must develop alternative
treatment approaches, such as agents that target specific
leukemia-associated abnormalities
and agents that Current Treatment Options in Oncology Acute Myeloid Leukemia Acute Myeloid Leukemia Patient
3
Kitap Bölümü

Kitap Bölümü
Kaynak
1:
Kaynak
2:
Kaynak
3:
Kaynak
4:
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Yıl :
2017
Acute myeloid leukemia This chapter summarizes the currently available data,
and presents recommendations regarding if
and when to pursue a transplant for persons with
acute myeloid
leukemia (AML), the optimal conditioning regimen, the graft type,
and use of alternative donors. of donor cells
and be minimally toxic to the recipient. Clinical Manual of Blood and Bone Marrow Transplantation
4
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2007
MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia Acute lymphoblastic
leukemia (ALL) is the most common
childhood cancer, whereas
acute
myeloid
leukemia (AML) is the most common
acute
leukemia in adults To understand the distinct mechanisms in leukemogenesis between ALL
and AML
and to identify markers for diagnosis
and
treatment, we performed a large-scale The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98
acute
leukemia samples covering
5
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Nephrology, Pediatrics, Perinatology and Child Health
Yıl :
2022
Acute kidney injury and childhood acute myeloid leukemia Acute kidney injury (AKI) appears to be particularly common in
children with
acute
myeloid
leukemia (AML), although the epidemiology data on this patient The objective of this study was to assess the prevalence
and factors associated with AKI in
childhood AML during chemotherapy
treatment. Age ≥ 10 years at diagnosis, impaired kidney function before
treatment,
and septic shock were strongly associated with AKI. Nephrology,Pediatrics, Perinatology and Child Health Acute kidney injury Childhood acute myeloid leukemia
6
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
National Academy of Sciences
Yazar(lar) :
Konu :
Biological Sciences, Science & Mathematics, General Science
Yıl :
2001
Molecular Emergence of Acute Myeloid Leukemia during Treatment for Acute Lymphoblastic Leukemia Therapy-related
acute
myeloid leukemias (t-AML) with translocations of the MLL gene are associated with the use of topoisomerase II inhibitors. We established the emergence of the malignant clone in a
child who developed t-AML with a t(11;19) (q23;p13.3) during
treatment for
acute lymphoblastic leukemia (ALL).
7
Konferans Bildirileri

Konferans Bildirileri
Kaynak
:
Yazar(lar) :
Konu :
Bioengineering, Computing and Processing
Yıl :
2007
Characterization of MYC expression in gefitinib versus Acute Myeloid Leukemia reveals novel therapeutic targets We conducted gene expression profiling
and pathway analysis of microarray data generated from a gefitinib versus M4-AML study. findings indicate that a therapeutic reduction of the human v-Myc oncoprotein correlated to molecular reversal of cell transformation within 24 hours of
treatment These targets, Src
and Jnk3, demonstrated strong interactions with gefitinib in small molecule/tyrosine kinase binding assays
and have proven critical Bioengineering,Computing and Processing 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering Medical treatment acute myeloid leukemia Acute Myeloid Leukemia
8
Tez

Tez

Kaynak
:
Yazar(lar) :
Konu :
Biyoteknoloji
Yıl :
2019
Evaluation of metabolite variation between acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines via triple quadrupole LC-MS While lymphatic
leukemia, originate from the lymphoid cell line,
acute
myeloid
leukemia (AML)
and chronic
myeloid
leukemia (CML) originate from the
myeloid Acute lymphoblastic
leukemia (ALL), on the other hand, is caused by abnormally uncontrolled
and excessive proliferation of lymphoblasts. ALL is responsible for 80% of
childhood
leukemia
and is common between 3-7 years of age.
9
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Pharmacology (medical), Oncology
Yıl :
2000
Acute myeloid leukemia in adults The
treatment outcome for most adults with
acute
myeloid
leukemia (AML) remains unacceptable. therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m2 as a continuous intravenous infusion over 24 hours for 7 days)
and Uncommon diseases such as AML, for which the outcome remains poor, should be
treated on clinical trials whenever possible. Current Treatment Options in Oncology Acute Myeloid Leukemia
10
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Oncology
Yıl :
2011
Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia To describe symptoms, diagnostic features,
treatments,
and outcomes of pneumatosis intestinalis (PI) in pediatric patients being
treated for
acute lymphoblastic leukemia (ALL)
and
acute
myeloid
leukemia (AML). PI is uncommon in
children with ALL or AML. Ultrasound is less sensitive than plain radiographs for diagnosis. Children Acute lymphoblastic leukemia Acute myeloid leukemia
11
Konferans Bildirileri

Konferans Bildirileri
Kaynak
:
Yazar(lar) :
Konu :
Computing and Processing, Signal Processing and Analysis
Yıl :
2020
Convolution Neural Network Models for Acute Leukemia Diagnosis Acute
leukemia is a cancer-related to a bone marrow abnormality. It is more common in
children
and young adults. This type of
leukemia generates unusual cell growth in a short period, requiring a quick start of
treatment. Acute Lymphoid
Leukemia (ALL)
and
Acute
Myeloid
Leukemia (AML) are the main responsible for deaths caused by this cancer. Computing and Processing,Signal Processing and Analysis 2020 International Conference on Systems, Signals and Image Processing (IWSSIP) Acute Leukemia diagnosis Acute Lymphoid Leukemia Acute Myeloid Leukemia
12
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Oncology, Hematology
Yıl :
2017
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia At the therapeutic intersection between
children
and older adults, the
treatment of adolescent
and young adults (AYAs) with
acute lymphoblastic
leukemia (ALL)
and
acute
myeloid
leukemia (AML) poses unique challenges due to their dismal outcome. Intensification of supportive care while maintaining
treatment intensity could further improve outcomes of AYAs with
leukemia. Adolescents and young adults (AYAs) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
13
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
General Medicine
Yıl :
2004
Highly refractory acute myeloid leukemia In this study we evaluated 103 patients suffering from
acute
myeloid
leukemia (AML) who did not respond to induction chemotherapy
and defined a subgroup of patients with highly refractory disease characterized by a persistence of more than 1G/L blast cells in the peripheral blood between days 12
and Four had de novo AML
and three secondary AML. Leukemia
14
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Cancer Research, Oncology
Yıl :
2015
Immunotherapy in acute myeloid leukemia Despite the remarkable progress made in some leukemias such as CML
and CLL, cytotoxic
treatment for AML remains essentially unchanged over the last 4 decades Allogeneic HSCT exploits major
and minor histocompatibility differences between the donor
and recipient in order to recognize
and eradicate malignancy. the
treatment of this disease.
15
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Cancer Research, Oncology
Yıl :
2006
Acute myeloid leukemia: Epidemiology and etiology Acute
myeloid leukemias (AMLs) are infrequent, yet highly malignant neoplasms responsible for a large number of cancer‐related deaths. It continuously shows 2 peaks in occurrence in early
childhood
and later adulthood. inversion of chromosome 16,
and
acute promyelocytic
leukemia with the translocation (15;17)).
16
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Hematology
Yıl :
2012
Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase We report the case of a 14-year-old female with
acute
myeloid
leukemia (AML)
and
myeloid sarcomas (MS) in the anterior mediastinum
and around numerous HLA-DR, but negative for CD34
and CD56. Aggressive MS in
childhood is rare
and refractory to existing AML chemotherapy. Acute myeloid leukemia Myeloid sarcoma
17
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Oncology
Yıl :
2002
Cytogenetics in acute myeloid leukemia Cytogenetic analysis is the most important diagnostic tool for determining prognosis in
acute
myeloid
leukemia (AML). The identification of specific chromosomal abnormalities
and their correlation with cytomorphologic features, immunophenotype,
and clinical outcome have clinical context,
and the new World Health Organization classification of AML uses cytogenetic abnormalities as a major criterion. Acute Myeloid Leukemia Acute Myelogenous Leukemia Acute Myeloid Leukemia Patient
18
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yayıncı:
Elsevier
Yazar(lar) :
Yıl :
2017
Familial myelodysplastic syndrome/acute myeloid leukemia A growing number of inherited genetic loci that contribute to myelodysplastic syndrome/
acute
myeloid
leukemia (MDS/AML) development in both
children International collaborative efforts to store germline tissue, document family histories,
and pool data are essential to progress in diagnosing
and
treating both hereditary
and sporadic forms of MDS/AML. Acute myeloid leukemia Hereditary myeloid malignancy syndromes
19
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Cancer Research, Oncology
Yıl :
1994
Acute myeloid leukemia in manitoba To the authors' knowledge, the natural history of myelosuppression
and infectious complications associated with the use of standard cytarabine (ARA‐C) plus daunorubicin (“7 + 3”) remission‐induction therapy for adult
acute
myeloid
leukemia (AML)
and high dose ARA‐C (HDARA‐C) consolidation has not been
20
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Pediatrics, Perinatology, and Child Health, Oncology, Hematology
Yıl :
2013
Epidemiology of childhood acute myeloid leukemia Although
leukemia is the most common
childhood cancer diagnosis, the subtype,
acute
myeloid
leukemia (AML), is less common
and fewer etiologic studies We searched the literature using PubMed for articles on
childhood AML
and reviewed 180 articles. Thorough analysis of genetic
and epigenetic factors is missing from this literature
and methodological issues are unresolved. Pediatrics, Perinatology, and Child Health,Oncology,Hematology
21
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Thomas Buchner
,
Wolfgang Hiddemann
,
Wolfgang Berdel
,
Bernhard Wormann
,
Claudia Schoch
,
Helmut Loffler
,
Torsten Haferlach
,
Andrea Schumacher
,
Peter Staib
,
Leopold Balleisen
,
Andreas Gruneisen
,
Herbert Rasche
,
Carlo Aul
,
Axel Heyll
,
Eva Lengfelder
,
Wolf-Dieter Ludwig
,
Georg Maschmeyer
,
Hartmut Eimermacher
,
Jochen Karow
,
Norbert Frickhofen
,
Wolf-Dietrich Hirschmann
,
Maria-Cristina Sauerland
Konu :
Hematology
Yıl :
2002
ACUTE MYELOID LEUKEMIA: TREATMENT OVER 60 Undertreatment of older patients with
acute
myeloid
leukemia (AML) can explain, in part, their inferior outcome when compared to that of younger patients and for the duration of postremission
treatment. A questionnaire study in patients with AML showed that, according to patients’ self‐assessment, intensive
and prolonged
treatment did not result in a diminished Reviews in Clinical and Experimental Hematology
22
Kitap Bölümü

Kitap Bölümü
Kaynak
:
Yayıncı:
John Wiley & Sons, Ltd
Yazar(lar) :
Yıl :
2013
Maintenance treatment in acute myeloid leukemia The use of postremission low‐dose maintenance
treatment (MT) in
childhood
acute
myeloid
leukemia (AML) has yielded mixed results. The studies by Perel et al.
and Wells et al. suggest that MT does not appear to improve overall survival (OS). The
acute promyelocytic
leukemia (APL) 93 trial was a randomized European study evaluating postremission therapy for patients with APL.
23
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Oncology
Yıl :
2002
Older adults with acute myeloid leukemia Acute
myeloid
leukemia (AML) occurs most frequently in older adults, with a median age range from 65 to 70 years. Both the disease
and its
treatment are distinct from their counterparts in young patients. Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches,
and Acute Myeloid Leukemia Acute Myelogenous Leukemia Acute Myeloid Leukemia Patient
24
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2015
Acute myeloid leukemia in infants: biology and treatment Children aged 0–2 years (i.e. infants) with
acute
myeloid
leukemia (AML) are a peculiar subgroup of patients in the
childhood AML scenario. Remarkable improvements have been achieved over the last 2 decades in the
treatment of these patients
and their outcome is becoming superimposable to that Treatment results
and toxicity data reported by major collaborative groups are also summarized
and compared. acute myeloid leukemia (AML) Treatment results
25
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Dergi:
Yazar(lar) :
Konu :
Oncology
Yıl :
2012
Acute Myeloid Leukemia with Normal Cytogenetics Acute
myeloid
leukemia (AML) is proving to be a heterogeneous disease process that is driven by various genetic mutations
and aberrant protein expression As we learn more, we hope to further categorize patients with normal karyotype AML into discrete risk categories that will help in
treatment decision making and further elucidate the necessity for hematopoietic cell transplantation. Acute myeloid leukemia
26
Dergi Makalesi

Dergi Makalesi
Kaynak
:
Yazar(lar) :
Konu :
Hematology, General Medicine
Yıl :
2009
Cytogenetics of pediatric acute myeloid leukemia Acute
myeloid
leukemia (AML) is a clinically
and genetically heterogeneous disease accounting for 15–20% of all
childhood
acute leukemias, while it is treatment selection in
childhood AML. the variable
treatment modalities used in different study groups.
27
Dergi Makalesi

Dergi Makalesi

Dergi:
Yazar(lar) :
Yıl :
2017
Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment Objective:
Leukemia is the most common pediatric malignancy
and a major cause of morbidity
and mortality in
children. Among all subtypes, a lack of consensus exists regarding the diagnosis
and
treatment of
acute
myeloid
leukemia (AML). Results: We described clonal evolution
and how it changes our view on leukemogenesis,
treatment responses,
and disease relapse. Acute Myeloid Leukemia